YGION Biomedical Secures €15M in Series A Funding to Advance Personalized Cancer Vaccine Technology

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...

May 21, 2024 | Tuesday | News
Telix's TLX592 Shows Promise in Prostate Cancer Treatment, Advances to Phase I/II Study

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...

May 14, 2024 | Tuesday | News
Recce Pharmaceuticals Initiates Phase I/II Trial with RECCE® 327, Administering Record Dosage for Urinary Tract Infections

First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to dat...

May 20, 2024 | Monday | News
InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech, a member of the Roche Group  announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being...

May 16, 2024 | Thursday | News
HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

  AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News
CytomX Therapeutics Collaborates with MSD for First-in-Human Trial of Novel CX-801 Cytokine to Revolutionize Cancer Treatment

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...

May 08, 2024 | Wednesday | News
Innovent Biologics Receives Breakthrough Therapy Designation for IBI343 in Advanced Gastric Cancer Treatment

Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...

May 07, 2024 | Tuesday | News
High Response Rate in Marginal Zone Lymphoma Patients: Initial Data Shows ZYNLONTA® Efficacy

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...

May 06, 2024 | Monday | News
Walgreens and Boehringer Ingelheim Forge Strategic Partnership to Democratize Clinical Trials

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...

May 03, 2024 | Friday | News
Beyfortus (nirsevimab) Proves Potent Against RSV Hospitalizations in Infants

New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the...

May 03, 2024 | Friday | News
HiberCell Initiates Phase 1b Trial for Combination Therapy in Advanced Kidney Cancer

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announ...

May 02, 2024 | Thursday | News
NKGen Biotech's SNK01 NK Cell Therapy Clears FDA IND Hurdle for Parkinson’s

The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. NKGen Biotech, Inc. , a clinical-stage biotechnology company focused on the dev...

April 30, 2024 | Tuesday | News
Abzena Introduces EpiScreen® 2.0: Transforms Immunogenicity Assessment for Advanced Therapeutics

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...

April 29, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in